Results 61 to 70 of about 7,224 (167)

SARS‐CoV‐2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Federica Frasca, Luca Maddaloni, Alessandra D'Auria, Matteo Fracella, Ginevra Bugani, Carmen Falvino, Valentina Baccolini, Giuseppe Migliara, Francesca Aloisi, Letizia Santinelli, Enrico Palermo, Luca Bortolani, Alessandro Lazzaro, Giancarlo Ceccarelli, Ombretta Turriziani, Claudio Maria Mastroianni, Guido Antonelli, Gabriella d'Ettorre, Carolina Scagnolari   +18 more
wiley   +1 more source

Type 2 Diabetes Mellitus: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 8, August 2026.
This graphical summary illustrates the multiorgan therapeutic landscape for Type 2 diabetes mellitus (T2D), integrating molecular pathogenesis with modern treatment strategies. It depicts how current interventions, including SGLT2 inhibitors, GLP‐1 receptor agonists, and insulin secretagogues, target key organs—kidney, pancreas, gastrointestinal tract,
Shinuan Fei, Xiyue Xiong, Lu Zhang, Jian Zhang, Lawrence W. C. Chan, Hong Jiang, Qingqing Xiong, Changtao Hu, Jie Chen, Sijun Yang   +9 more
wiley   +1 more source

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 4, Page 517-526, August 2026.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi, Allison Carroll, Vy H. Nguyen, Megan Michta, Xuan Q. Zhang, Young‐Suk Lim, Raymond T. Chung   +6 more
wiley   +1 more source

Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date

HIV/AIDS: Research and Palliative Care, 2018
Lucas Hill,1 Shawn R Smith,1 Maile Young Karris2 1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA; 2Department of Medicine, University of California San Diego, San Diego, CA, USA Abstract ...
Hill L, Smith SR, Karris MY
doaj  

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, Volume 27, Issue 8, Page 1241-1252, August 2026.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody

Emerging Infectious Diseases
A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine ...
Eisuke Adachi, Ayako Sedohara, Kotaro Arizono, Kazuaki Takahashi, Amato Otani, Yoshiaki Kanno, Makoto Saito, Michiko Koga, Hiroshi Yotsuyanagi   +8 more
doaj   +1 more source

Monitoring of the Cascade of Care in Patients With Chronic HBV in Primary Care Clinics in Australia

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT To achieve hepatitis B virus (HBV) elimination in Australia, a shift from hospital to community‐based care is needed. This study aimed to describe the prevalence of chronic HBV and uptake of the cascade of care in primary care patients. This prospective cohort study was conducted in 76 urban and regional primary care clinics across Victoria ...
Dina Moussa, Jack Wallace, Jacqui Richmond, Joseph S. Doyle, Long Nguyen, Douglas Boyle, Mark A. Stoové, Jason Asselin, Victoria Polkinghorne, Marvad Ahad, Susanne Glasgow, Kate New, Lena Sanci, Matt Penn, John Furler, Alexander Thompson, Margaret Hellard, Jess Howell   +17 more
wiley   +1 more source

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate

Drugs in R&D
Background and Objectives The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus.
Derek E. Murrell, Benjamin C. Kennard, Maria E. Bertoni, David B. Cluck, Jonathan P. Moorman, Stacy D. Brown, Kesheng Wang, Michelle M. Duffourc, Sam Harirforoosh   +8 more
doaj   +1 more source

Tenofovir alafenamide for hepatitis B: evolution or revolution? [PDF]

The Lancet Gastroenterology & Hepatology, 2016
Chronic hepatitis B infection remains a global health burden despite existence of an effective vaccine. Infection with chronic hepatitis B and its sequelae lead to almost 800 000 deaths annually. Over the past decades, treatment of chronic hepatitis B has evolved considerably.
openaire   +3 more sources

Distinct Lipidomic Profiles between People Living with HIV Treated with E/C/F/TAF or B/F/TAF: An Open-Label Prospective Cohort Study

Infectious Diseases and Therapy
Introduction Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) has been increasingly replaced by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in the treatment of human immunodeficiency virus (HIV) owing to its more ...
Zhikai Wan, Junwei Su, Xueling Zhu, Xiang Liu, Yongzheng Guo, Dairong Xiang, Xiaotang Zhou, Xiaorong Peng, Ran Tao, Qing Cao, Guanjing Lang, Ying Huang, Biao Zhu   +12 more
doaj   +1 more source